IEH Biopharma 
Welcome,         Profile    Billing    Logout  
 3 Products   2 Diseases  3 Products   1 Trial   199 News 
16 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
topiramate/phentermine / Generic mfg.
EMPOWER-T2D, NCT04531176: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Terminated
4
74
US
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
The Cleveland Clinic
Type 2 Diabetes, Obesity
08/22
08/23
NCT05215418: A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Completed
4
565
US
VI-0521, Qsymia, Phentermine and topiramate, Phentermine, Placebo
VIVUS LLC
Blood Pressure
04/23
04/23
NCT05378503: Phase IV Study of Qsymia in Obese Patients

Completed
4
232
RoW
Qsymia 3.75Mg-23Mg Extended Release Capsule, Low dose titration, Qsymia 7.5Mg-46Mg Extended Release Capsule, Low dose maintenance, Qsymia 11.25Mg-69Mg Extended Release Capsule, High dose titration, Qsymia 15Mg-92Mg Extended Release Capsule, High dose maintenance, Placebo
Alvogen Korea
Obesity
10/23
10/23
NCT05579249: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed
4
500
US
Semaglutide, Wegovy, Orlistat, Xenical, Phentermine/Topiramate, Qsymia, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda
Novo Nordisk A/S
Obesity
11/24
11/24
STAY-LEAN, NCT06854614: Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial ( Trial)

Recruiting
4
150
US
Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Qsymia, Naltrexone-Bupropion Combination, Contrave, Orlistat, Xenical
The Cleveland Clinic
Obesity
12/25
12/26
PROJECT-BARI, NCT05975580: Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

Recruiting
4
120
US
Topiramate, Phentermine, Placebo
University of California, Irvine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
04/27
07/27
2012-003946-34: A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.

Ongoing
3
16000
Europe
Capsule, Qsymia®
VIVUS, Inc., VIVUS, Inc.
Cardiovascular Disease in overweight and obese subjects, Health of an overweight or obese subject's heart and/or vascular system (blood vessels), Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT06905626: Weight Gain Prevention in Adolescents and Young Adults

Not yet recruiting
3
140
NA
Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule, Qsymia, Placebo
University of Minnesota
Healthy Volunteers
05/29
05/30
NCT04721873: Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

Recruiting
2a
40
US
Phentermine-Topiramate, Placebo
University of California, San Diego
Colitis, Ulcerative, Obesity
06/24
06/24
NCT01950520: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Completed
2
47
US
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteers
12/22
06/24
NCT06299891: Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Recruiting
2
24
US
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo, Matching blinded placebo capsules
Seattle Children's Hospital, Children's Hospital of Philadelphia
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
02/26
05/26
NCT04298203: Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

Active, not recruiting
2
100
US
Phentermine-Topiramate, Qsymia, Meal Replacement Therapy, Placebo
University of Minnesota
Obesity
06/26
06/27
NCT05834062: Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

Withdrawn
2
140
US
Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
University of Minnesota
Obesity, Adolescent
08/26
08/27
NCT04881799: Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

Active, not recruiting
1
13
US
Phentermine/Topiramate (Qsymia), Placebo
University of Minnesota
Pediatric Obesity
06/26
06/27
NCT05756764: Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting
N/A
30
US
Semaglutide, Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy, Phentermine-Topiramate combination, Qsymia, Phentermine, Lomaira, Adipex-P, Tirzepatide, Mounjaro, Zepbound, GIP/GLP-1 RA, Topiramate, Topamax, Trokendi XR, Qudexy XR, Diethylpropion, Tenuate, Diethylcathinone, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda, Victoza
Louisiana State University Health Sciences Center in New Orleans, Tulane University, Pennington Biomedical Research Center, Ochsner Health System
Obesity
06/25
07/25
NCT05139420: Risk of Metabolic Adaptation After Weight Loss

Suspended
N/A
60
US
lifestyle intervention with meal replacement program
Medical College of Wisconsin
Weight Loss, Obesity
11/29
11/29
VI-1121 / IEH Biopharma
No trials found
Stendra (avanafil) / IEH Biopharma, Menarini, Endo
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
topiramate/phentermine / Generic mfg.
EMPOWER-T2D, NCT04531176: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

Terminated
4
74
US
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
The Cleveland Clinic
Type 2 Diabetes, Obesity
08/22
08/23
NCT05215418: A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Completed
4
565
US
VI-0521, Qsymia, Phentermine and topiramate, Phentermine, Placebo
VIVUS LLC
Blood Pressure
04/23
04/23
NCT05378503: Phase IV Study of Qsymia in Obese Patients

Completed
4
232
RoW
Qsymia 3.75Mg-23Mg Extended Release Capsule, Low dose titration, Qsymia 7.5Mg-46Mg Extended Release Capsule, Low dose maintenance, Qsymia 11.25Mg-69Mg Extended Release Capsule, High dose titration, Qsymia 15Mg-92Mg Extended Release Capsule, High dose maintenance, Placebo
Alvogen Korea
Obesity
10/23
10/23
NCT05579249: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Completed
4
500
US
Semaglutide, Wegovy, Orlistat, Xenical, Phentermine/Topiramate, Qsymia, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda
Novo Nordisk A/S
Obesity
11/24
11/24
STAY-LEAN, NCT06854614: Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial ( Trial)

Recruiting
4
150
US
Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Qsymia, Naltrexone-Bupropion Combination, Contrave, Orlistat, Xenical
The Cleveland Clinic
Obesity
12/25
12/26
PROJECT-BARI, NCT05975580: Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

Recruiting
4
120
US
Topiramate, Phentermine, Placebo
University of California, Irvine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
04/27
07/27
2012-003946-34: A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.

Ongoing
3
16000
Europe
Capsule, Qsymia®
VIVUS, Inc., VIVUS, Inc.
Cardiovascular Disease in overweight and obese subjects, Health of an overweight or obese subject's heart and/or vascular system (blood vessels), Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT06905626: Weight Gain Prevention in Adolescents and Young Adults

Not yet recruiting
3
140
NA
Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule, Qsymia, Placebo
University of Minnesota
Healthy Volunteers
05/29
05/30
NCT04721873: Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

Recruiting
2a
40
US
Phentermine-Topiramate, Placebo
University of California, San Diego
Colitis, Ulcerative, Obesity
06/24
06/24
NCT01950520: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

Completed
2
47
US
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteers
12/22
06/24
NCT06299891: Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Recruiting
2
24
US
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo, Matching blinded placebo capsules
Seattle Children's Hospital, Children's Hospital of Philadelphia
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
02/26
05/26
NCT04298203: Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity

Active, not recruiting
2
100
US
Phentermine-Topiramate, Qsymia, Meal Replacement Therapy, Placebo
University of Minnesota
Obesity
06/26
06/27
NCT05834062: Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity

Withdrawn
2
140
US
Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy
University of Minnesota
Obesity, Adolescent
08/26
08/27
NCT04881799: Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity

Active, not recruiting
1
13
US
Phentermine/Topiramate (Qsymia), Placebo
University of Minnesota
Pediatric Obesity
06/26
06/27
NCT05756764: Anti-obesity Pharmacotherapy and Inflammation

Active, not recruiting
N/A
30
US
Semaglutide, Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy, Phentermine-Topiramate combination, Qsymia, Phentermine, Lomaira, Adipex-P, Tirzepatide, Mounjaro, Zepbound, GIP/GLP-1 RA, Topiramate, Topamax, Trokendi XR, Qudexy XR, Diethylpropion, Tenuate, Diethylcathinone, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda, Victoza
Louisiana State University Health Sciences Center in New Orleans, Tulane University, Pennington Biomedical Research Center, Ochsner Health System
Obesity
06/25
07/25
NCT05139420: Risk of Metabolic Adaptation After Weight Loss

Suspended
N/A
60
US
lifestyle intervention with meal replacement program
Medical College of Wisconsin
Weight Loss, Obesity
11/29
11/29
VI-1121 / IEH Biopharma
No trials found
Stendra (avanafil) / IEH Biopharma, Menarini, Endo
No trials found

Download Options